Dr. Roman Shapiro, MD

Dr. Shapiro practices at Brigham and Women's Hospital in Boston, Massachusetts, part of Mass General Brigham.

Dr. Shapiro's NPI, 1932765682, was assigned on May 17, 2019. Dr. Shapiro holds Massachusetts license 278988.

Dr. Shapiro's primary practice is Brigham and Women's Hospital, at 75 Francis Street, Boston, MA 02115 in Suffolk County. The practice phone is (617) 732-5500.

Dr. Shapiro's primary practice is Brigham and Women's Hospital in Boston, Massachusetts, part of Mass General Brigham. Dr. Shapiro is also affiliated with Dana-Farber Cancer Institute. The medical group on file is Binney Medical Group. Dmand AI also links Dr. Shapiro to 1 more hospital and 1 hospital outpatient department, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shapiro practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Shapiro's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Shapiro is licensed in Massachusetts.

CMS data shows 420 Medicare services from Dr. Shapiro across 6 procedure codes in 2024, for 117 Medicare patients. Medicare paid $33,142 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 117 Medicare patients who saw Dr. Shapiro in 2024. The largest group is 65 to 74, with 79 patients. 72% of them have high cholesterol, and 71% have high blood pressure. 13% are also on Medicaid. Their average risk score is 2.87, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Shapiro's median patient age at 67, with 36% women.

In 2024, Dr. Shapiro wrote 285 Medicare Part D claims for 53 patients. 87% of them were for generic drugs. CMS names the drug for 156 of them, across 7 drugs with 11 or more claims each, at $452,318 in total drug cost. In 2023, CMS named 153 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Shapiro for performance year 2024, reported as part of a group. Dr. Shapiro accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 37 papers to Dr. Shapiro, published from 2014 to 2025. 2023 was the busiest year, with 6. The most frequent topics are Hematopoietic Stem Cell Transplantation, Graft vs Host Disease and Killer Cells, Natural. Dr. Shapiro has published most often in Blood Adv. Dr. Shapiro's most frequent co-authors are John Koreth, MBBS, Robert J. Soiffer, MD and Joseph Harry Antin, MD.

Dmand AI links Dr. Shapiro to 2 clinical trials. 2 are still active or recruiting. Conditions studied include Graft vs Host Disease, Leukemia, Myelomonocytic, Juvenile and Immune System Diseases.

CMS Open Payments shows 3 general payments to Dr. Shapiro from 1 drug or device company in 2025. Consulting fees make up the largest share, 93% of the total. Sanofi and Genzyme US Companies paid the most, $8,022.